Evonetix wins Best Emerging Synthetic Biology Company at the OBN Awards
- Posted on 12 October, 2018
London, UK, 12th October 2018 / Sciad Newswire / SynbiCITE would like to congratulate Evonetix on winning ‘Best Emerging Synthetic Biology Company’ at the 10th Annual OBN Awards Ceremony last night. The award recognises the emerging UK industrial or synthetic biology company that demonstrates the most promise. Entrants were assessed on capital raised, level of innovation and their contribution to the bioeconomy.
Evonetix is developing a revolutionary gene synthesis platform based on a novel silicon array. The controlled process results in high fidelity DNA sequences, and allows parallelism in DNA synthesis, enabling a high throughput process. This technology has the potential to influence a number of industries across the synthetic biology space including drug development, industrial biotechnology, agriculture and food production.
“Evonetix’s technology demonstrates the potential of synthetic biology to create effective new ways to address some of the world’s most significant unmet needs” commented Professor Paul Freemont, Co-Director of SynbiCITE. “This award recognises Evonetix’s highly disruptive technology and is an indicator of the UK’s strength and depth in engineering biology.”
Professor Richard Kitney, Co-Director of SynbiCITE, added, “The success of Evonetix is a good example of how the UK’s strategy, and that of SynbiCITE, is beginning to pay off in developing and supporting start-ups and SMEs. The three finalists; Evonetix, OxSyBio and Oxford Genetics are all examples of UK companies that have become highly successful, and we would like to offer our congratulations to them all.”
Share this article:
People also read
The SynbiCITE ‘4-Day MBA, More Business Acumen’ Course
The SynbiCITE ‘4-Day MBA: More Business Acumen’ Course, 8th-12th December 2019In 2015, 35% of employers in engineering and technology-based business s...
Data-driven design and the opportunities it presents for biotech companies
Professor Paul Freemont, Co-Director of SynbiCITE, discussed the synthetic biology industry and the opportunities it is creating in a recently paper published in The Emerging Topics in Life Sciences entitled “Synthetic biology industry: data-driven design is creating new opportunities in biotechnology”.
The Cell Factories of the Future
Professor Paul Freemont, Co-Director of SynbiCITE, is the lead author of a recent article published by the World Economic Forum on this subject, entitled “How scientists are turning living cells into the tiny factories of the future”.